{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T11:08:02Z","timestamp":1745233682707,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s12325-021-01647-4","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T21:44:51Z","timestamp":1613684691000},"page":"1690-1700","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["HCV Viral Load Greater Than 1000\u00a0IU\/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1559-3983","authenticated-orcid":false,"given":"Jake R.","family":"Morgan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Savinkina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Gabriela","family":"Pires dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonjelle","family":"Shilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Linas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"issue":"3","key":"1647_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"HCVC Polaris Observatory","year":"2017","unstructured":"Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161\u201376.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1647_CR2","unstructured":"World Health Organization. Global Hepatitis Report 2017. Available at: http:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/. Accessed Jan 27, 2021."},{"key":"1647_CR3","unstructured":"Polaris Observatory. Centers for Disease Analysis. http:\/\/cdafound.org\/polaris\/. Accessed Jan 27, 2021."},{"issue":"Suppl 2","key":"1647_CR4","doi-asserted-by":"publisher","first-page":"e25058","DOI":"10.1002\/jia2.25058","volume":"21","author":"S Fourati","year":"2018","unstructured":"Fourati S, Feld JJ, Chevaliez S, Luhmann N. Approaches for simplified HCV diagnostic algorithms. J Int AIDS Soc. 2018;21(Suppl 2):e25058.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"1647_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/0973-6247.126683","volume":"8","author":"E Gupta","year":"2014","unstructured":"Gupta E, Bajpai M, Choudhary A. Hepatitis C virus: screening, diagnosis, and interpretation of laboratory assays. Asian J Transfus Sci. 2014;8(1):19\u201325.","journal-title":"Asian J Transfus Sci"},{"issue":"1","key":"1647_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jhep.2019.02.011","volume":"71","author":"JM Freiman","year":"2019","unstructured":"Freiman JM, Wang J, Easterbrook PJ, Horsburgh CR, Marinucci F, White LF, et al. Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: analysis of a global dataset. J Hepatol. 2019;71(1):62\u201370.","journal-title":"J Hepatol"},{"key":"1647_CR7","unstructured":"World Health Organization. Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries. 2018. Available from: http:\/\/www.who.int\/hepatitis\/publications\/hep-c-access-report-2018\/en\/. Accessed on Jan 27, 2021."},{"key":"1647_CR8","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol [ahead of print]. 2020. https:\/\/doi.org\/10.1016\/j.jhep.2020.08.018.","DOI":"10.1016\/j.jhep.2020.08.018"},{"issue":"4","key":"1647_CR9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa1702417","volume":"378","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, et al. Glecaprevir-Pibrentasvir for 8 or 12\u00a0Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018;378(4):354\u201369.","journal-title":"N Engl J Med"},{"issue":"1","key":"1647_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2468-1253(18)30341-8","volume":"4","author":"T Asselah","year":"2019","unstructured":"Asselah T, Lee SS, Yao BB, Nguyen T, Wong F, Mahomed A, et al. Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4(1):45\u201351.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"1647_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/hep.29081","volume":"66","author":"F Poordad","year":"2017","unstructured":"Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment [supplement]. Hepatology. 2017;66(2):389\u201397.","journal-title":"Hepatology"},{"key":"1647_CR12","doi-asserted-by":"crossref","unstructured":"Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, et al. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology. 2016;151(4):651\u20139 e1.","DOI":"10.1053\/j.gastro.2016.07.020"},{"issue":"9","key":"1647_CR13","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S2468-1253(20)30086-8","volume":"5","author":"L Wei","year":"2020","unstructured":"Wei L, Wang G, Alami NN, Xie W, Heo J, Xie Q, et al. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). Lancet Gastroenterol Hepatol. 2020;5(9):839\u201349.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"4","key":"1647_CR14","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/hep.30046","volume":"68","author":"N Reau","year":"2018","unstructured":"Reau N, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, Angus P, et al. Glecaprevir\/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection. Hepatology. 2018;68(4):1298\u2013307.","journal-title":"Hepatology"},{"issue":"10","key":"1647_CR15","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","volume":"17","author":"X Forns","year":"2017","unstructured":"Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17(10):1062\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"15","key":"1647_CR16","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","volume":"377","author":"E Gane","year":"2017","unstructured":"Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Brau N, Brown A, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377(15):1448\u201355.","journal-title":"N Engl J Med"},{"issue":"5","key":"1647_CR17","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/liv.14320","volume":"40","author":"E Lawitz","year":"2020","unstructured":"Lawitz E, Flisiak R, Abunimeh M, Sise ME, Park JY, Kaskas M, et al. Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection. Liver Int. 2020;40(5):1032\u201341.","journal-title":"Liver Int"},{"issue":"3","key":"1647_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","volume":"72","author":"RS Brown Jr","year":"2020","unstructured":"Brown RS Jr, Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, et al. Glecaprevir\/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol. 2020;72(3):441\u20139.","journal-title":"J Hepatol"},{"key":"1647_CR19","doi-asserted-by":"publisher","first-page":"100257","DOI":"10.1016\/j.aohep.2020.09.002","volume":"20","author":"M Peribanez-Gonzalez","year":"2020","unstructured":"Peribanez-Gonzalez M, Cheinquer H, Rodrigues L, Lima MP, Alvares-da-Silva MR, Madruga J, et al. Efficacy and safety of glecaprevir\/pibrentasvir in treatment-naive adults with chronic hepatitis C virus genotypes 1\u20136 in Brazil. Ann Hepatol. 2020;20:100257.","journal-title":"Ann Hepatol."},{"issue":"2","key":"1647_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/hep.29081","volume":"66","author":"F Poordad","year":"2017","unstructured":"Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017;66(2):389\u201397.","journal-title":"Hepatology"},{"issue":"4","key":"1647_CR21","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/hep.29671","volume":"67","author":"F Poordad","year":"2018","unstructured":"Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hezode C, et al. Glecaprevir\/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology. 2018;67(4):1253\u201360.","journal-title":"Hepatology"},{"issue":"7","key":"1647_CR22","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/cid\/ciy220","volume":"67","author":"JK Rockstroh","year":"2018","unstructured":"Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, et al. Efficacy and safety of glecaprevir\/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus Type 1: the EXPEDITION-2 study. Clin Infect Dis. 2018;67(7):1010\u20137.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1647_CR23","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/hep.29541","volume":"67","author":"D Wyles","year":"2018","unstructured":"Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, et al. Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: a partially randomized phase 3 clinical trial. Hepatology. 2018;67(2):514\u201323.","journal-title":"Hepatology"},{"issue":"4","key":"1647_CR24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00535-017-1391-5","volume":"53","author":"K Chayama","year":"2018","unstructured":"Chayama K, Suzuki F, Karino Y, Kawakami Y, Sato K, Atarashi T, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 2018;53(4):557\u201365.","journal-title":"J Gastroenterol."},{"issue":"4","key":"1647_CR25","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s00535-017-1396-0","volume":"53","author":"H Kumada","year":"2018","unstructured":"Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H, et al. Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol. 2018;53(4):566\u201375.","journal-title":"J Gastroenterol."},{"issue":"3","key":"1647_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","volume":"16","author":"T Asselah","year":"2018","unstructured":"Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, et al. Efficacy of glecaprevir\/pibrentasvir for 8 or 12\u00a0Weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis [supplement]. Clin Gastroenterol Hepatol. 2018;16(3):417\u201326.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"1647_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","volume":"67","author":"PY Kwo","year":"2017","unstructured":"Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis. J Hepatol. 2017;67(2):263\u201371.","journal-title":"J Hepatol."},{"issue":"2","key":"1647_CR28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/hep.29510","volume":"67","author":"H Toyoda","year":"2018","unstructured":"Toyoda H, Chayama K, Suzuki F, Sato K, Atarashi T, Watanabe T, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology. 2018;67(2):505\u201313.","journal-title":"Hepatology"},{"issue":"15","key":"1647_CR29","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","volume":"377","author":"E Gane","year":"2017","unstructured":"Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Brau N, Brown A, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment [supplement]. N Engl J Med. 2017;377(15):1448\u201355.","journal-title":"N Engl J Med."},{"issue":"12","key":"1647_CR30","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1007\/s12325-019-01123-0","volume":"36","author":"RJ Fontana","year":"2019","unstructured":"Fontana RJ, Lens S, McPherson S, Elkhashab M, Ankoma-Sey V, Bondin M, et al. Efficacy and safety of 8\u00a0weeks of glecaprevir\/pibrentasvir in treatment-naive, HCV-infected patients with APRI <\/= 1 in a single-arm, open-label. Multicenter Study Adv Ther. 2019;36(12):3458\u201370.","journal-title":"Multicenter Study Adv Ther."},{"issue":"Suppl 1","key":"1647_CR31","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1186\/s12879-017-2779-9","volume":"17","author":"JR Morgan","year":"2017","unstructured":"Morgan JR, Servidone M, Easterbrook P, Linas BP. Economic evaluation of HCV testing approaches in low and middle income countries. BMC Infect Dis. 2017;17(Suppl 1):697.","journal-title":"BMC Infect Dis."},{"issue":"2","key":"1647_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/cid\/ciz385","volume":"70","author":"PR Harrington","year":"2020","unstructured":"Harrington PR, Komatsu TE, Sun H, Naeger LK. Hepatitis C virus RNA levels following virologic failure with direct-acting antivirals: implications for lower sensitivity diagnostic assays. Clin Infect Dis. 2020;70(2):327\u201330.","journal-title":"Clin Infect Dis."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01647-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-021-01647-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01647-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T14:07:37Z","timestamp":1614866857000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-021-01647-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1647"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01647-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"2 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}